First the Activists, Now The Competition: Actelion Faces Continued Challenges
This article was originally published in The Pink Sheet Daily
Executive Summary
Actelion may have rebuffed activist shareholders Elliott Advisors, but it now faces growing competition in its core PAH franchise.
You may also be interested in...
Business News, In Brief
Some companies must answer to shareholders as blockbuster drugs come off patent, while others look to their pipeline’s future in diverse collaborations.
Actelion Passes On Trophos Acquisition After Failed Lou Gehrig's Study
Actelion decides not to exercise its option to acquire the Marseille-based French biotech Trophos after the failure of that company's lead compound, olesoxime, in a Phase III study in amyotrophic lateral sclerosis
The End of The Euro: What Might It Mean For Pharma?
Companies struggle on how even to begin assessing impact of a possible Euro break-up.